UCB's Vimpat prevails in patent challenge--but IPR threat still lurks

Justice statue with sword and scales

It’s a great day for Belgium’s UCB pharma, thanks to a U.S. District Court patent ruling. In fact, it’s one of the company's best days in years.

Sunday, UCB announced that a Delaware District Court had rejected challenges to its patent on anti-seizure drug Vimpat--one of four key products for the Brussels-based drugmaker.

And investors cheered the news, sending UCB shares to the highest height they’ve reached since 2009.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

With the decision, Vimpat’s IP shield is now safe through 2022--at least, for now--and UCB is expecting big things from the med before that time comes. The company’s expecting the med to rake in peak sales of more than €1.2 billion by 2020, it said in its annual report.

In 2015, it generated €679 million in annual sales, joining products Cimzia, Neupro and Keppra to combine for 77% of UCB’s global net sales.

UCB isn’t totally out of the woods, though. In late May, New York-based generics maker Argentum Pharmaceuticals won an inter partes review of Vimpat’s patent protection by the U.S. Patent & Trademark Office (PTO)’s Patent Trial & Appeal Board (PTAB). And that decision may not be handed down until next May.

Still, court’s decision is a “long-awaited sentiment boost” for UCB, whose shares had fallen by about 17% so far this year, Citigroup analysts wrote in a Monday note seen by Bloomberg. Despite the lingering risk of patent invalidation, they wrote, “we expect market confidence to improve.”

- read UCB's release
- get more from Bloomberg

Related Articles:
Belgium's UCB calls it quits on $1.53B sale of U.S. generic drug unit
UCB joins pharma's slimdown craze, unloads U.S. generic drug business for $1.53B
UCB taps biopharma chief to step up to CEO job, prep for new launches


Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.